News | Artificial Intelligence | June 12, 2020

RapidAI Acquires EndoVantage

RapidAI acquires comprehensive aneurysm management innovator and expands scope to include aneurysm, extending its leadership in cerebrovascular imaging

RapidAI acquires comprehensive aneurysm management innovator and expands scope to include aneurysm, extending its leadership in cerebrovascular imaging

June 12, 2020 — RapidAI announced the acquisition of EndoVantage, developer of the Find, Track and Treat comprehensive cerebral aneurysm management platform. A major neurological condition, it is estimated that 1 in 50 people in the U.S. has an unruptured cerebral aneurysm, with one rupturing and resulting in a brain hemorrhage every 18 minutes. With this news, RapidAI continues to expand its scope, from ischemic stroke to hemorrhagic stroke and now aneurysm.  

In 2019, RapidAI introduced Rapid ICH, the next step in artificial intelligence (AI)-powered imaging technology for hemorrhages. Now with the acquisition of EndoVantage, the company will also add a concentration on aneurysm. Started at Mayo Clinic and Arizona State University, EndoVantage has developed a powerful award-winning computational platform that provides comprehensive cerebral aneurysm management, automating the entire workflow from initial assessment, growth monitoring, to treatment planning. It utilizes CTA and MRA scans to deliver results that help physicians find and track aneurysm progression, and leverages data from 3-D rotational angiograms to deliver detailed 3-D models of a patient’s vasculature and allow presurgical planning for the repair of the aneurysm.

“By adding the incredible technology developed by EndoVantage to the Rapid platform, we strengthen our position as the global leader in cerebrovascular imaging,” said Don Listwin, CEO of RapidAI. “We can offer hospitals a complete portfolio of products—encompassing ischemic stroke, hemorrhagic stroke, and aneurysm—providing an end-to-end solution that will drive better patient outcomes across the spectrum of cerebrovascular disorders.”

“We are very excited to join the Rapid platform of technology.  EndoVantage covers the spectrum of cerebral aneurysm care from diagnosis through treatment, which helps physicians decide how best to treat their patients,” said Brian Chong, M.D., cofounder, EndoVantage. "Each patient’s aneurysm is unique, like the patient. Our technology augments a physician’s clinical acumen and experience helping them determine the best plan for each patient.”

For more information: www.rapidai.com

Related Content

SmartXR uses a unique combination of hardware and AI-powered software to lighten radiographers’ workloads and provide image acquisition support.

SmartXR uses a unique combination of hardware and AI-powered software to lighten radiographers’ workloads and provide image acquisition support. 

Feature | Digital Radiography (DR) | May 04, 2021 | By Melinda Taschetta-Millane
The COVID-19 pandemic brought about an uptick in
The promise of personalized medicine, with its potential for treatments tailored to individual patients’ genomic footprints to generate better outcomes, has long tantalized the life sciences industry

Image courtesy of HealthMyne

Feature | Information Technology | May 04, 2021 | By Rose Higgins
The promise of...
Asheville Radiology Associates announced the unveiling of a new brand including a name, logo and website. The adopted name of Asheville Radiology Associates is now ARA Health Specialists (ARAHS). The updated name more closely reflects ARAHS’ role in leading healthcare in Western North Carolina.
News | Radiology Business | May 03, 2021
May 3, 2021 — Asheville Radiology Associates announced the unveiling of a new brand including a name, logo and websit
A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Image used with permission of RSNA.

A 37-year-old woman developed a new, palpable left supraclavicular lymphadenopathy lump five days after her first dose of the Moderna COVID-19 vaccine in the left arm. On the day of vaccination, the patient was asymptomatic. This is an example of how the vaccine can mimic cancer and swollen lymph nodes. Read more about this case study. Image used with permission of RSNA.

Feature | Coronavirus (COVID-19) | May 03, 2021 | By Dave Fornell, Editor
While the mass COVID-19 vaccinat
The contrast agents global market is expected to grow at a high single digit CAGR from 2020 to 2027 to reach $7,033.5 million by 2027 due to the increasing incidence and prevalence of chronic diseases and demand for diagnostic and interventional radiology procedures, increase in aging population, expansion of contrast agent indications, the growth of medical imaging in the emerging market, increasing research activities and favorable reimbursement

image courtesy of Guerbet

News | Contrast Media | May 03, 2021
Chemical substances that improve the visibility of specific organs, tissues, or blood vessels during a diagnostic or
News | Artificial Intelligence | April 30, 2021
April 30, 2021 — Canon Medical is bringing the power of accessible...
The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

The Women’s Heart Attack Research Program (HARP) study shows combining OCT and cardiac MRI can help detect the underlying cause of heart attacks in women who did not have blocked arteries.

News | Cardiac Imaging | April 30, 2021
April 30, 2021 — In almost 10 percent of...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc